Related Experiment Video
Updated: Jan 5, 2026
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
612
Germline testing for prostate cancer prognosis: implications for active surveillance
1Program for Personalized Cancer Care and Division of Urology, NorthShore University HealthSystem, Evanston, Illinois, USA.
The Canadian Journal of Urology
|October 21, 2019
Summary
Germline variants significantly impact prostate cancer aggressiveness and progression. Genetic testing can help predict grade reclassification in patients on active surveillance, guiding clinical management for localized prostate cancer.
Area of Science:
- Genetics
- Oncology
- Urology
Background:
- Prostate cancer aggressiveness and progression are influenced by genetic factors.
- Understanding germline variants is crucial for personalized treatment strategies.
Purpose of the Study:
- To review germline variants associated with prostate cancer aggressiveness.
- To discuss the clinical implications of germline variants in active surveillance.
- To propose recommendations for germline testing in localized prostate cancer.
Main Methods:
- Evidence-based review of recent manuscripts and original studies.
- Analysis of germline variants linked to prostate cancer progression.
- Evaluation of clinical utility in predicting grade reclassification.
Main Results:
- Identified significant germline variants associated with prostate cancer aggressiveness.
- Demonstrated the role of germline variants in predicting grade reclassification for active surveillance patients.
- Established the clinical relevance of germline testing for localized prostate cancer management.
Conclusions:
- Germline variants are key predictors of prostate cancer behavior.
- Germline testing offers valuable insights for active surveillance and treatment decisions.
- Evidence-based recommendations for germline testing can optimize clinical management.
